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Abstract
Background: We examine the practical application of multiparametric MRI (mpMRI) prostate
biopsy data using established pre-RP nomograms and its potential implications on RP
intraoperative decision-making. We hypothesize that current nomograms are suboptimal in
predicting outcomes with mpMRI targeted biopsy (TBx) data.
Materials and methods: Patients who underwent mpMRI-based TBx prior to RP were
assessed using the MSKCC and Briganti nomograms with the following iterations: (1) Targeted
(T) (targeted only), (2) Targeted and Systematic (TS) and (3) Targeted Augmented (TA) (targeted
core data; assumed negative systematic cores for 12 total cores). Nomogram outcomes,
lymph node involvement (LNI), extracapsular extension (ECE), organ-confined disease (OCD),
seminal vesicle invasion (SVI), were compared across iterations. Clinically significant impact
on management was defined as a change in LNI risk above or below 2% (Δ2) or 5% (Δ5).
Results: A total of 217 men met inclusion criteria. Overall, the TA iteration had more
conservative nomogram outcomes than the T. Moreover, TA better predicted RP pathology for
all four outcomes when compared with the T. In the entire cohort, Δ2 and Δ5 were 16.6–25.8%
and 20.3–39.2%, respectively. In the subset of 190 patients with targeted and systematic cores,
TA was a better approximation of TS outcomes than T in 71% (MSKCC) and 82% (Briganti) of
patients.
Conclusion: In established pre-RP nomograms, mpMRI-based TBx often yield variable and
discordant results when compared with systematic biopsies. Future nomograms must better
incorporate mpMRI TBx core data. In the interim, augmenting TBx data may serve to bridge
the gap.
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Introduction
Radical prostatectomy (RP) remains a standard
of care therapy for clinically localized prostate
cancer (PCa).1 However, the role of pelvic
lymph node dissection (PLND) at the time of
RP remains controversial, as its oncologic benefit remains unclear.2–4 Moreover, significant
variability exists among international guidelines
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regarding indications for PLND at the time of
RP. The National Comprehensive Cancer
Network (NCCN) and European Association of
Urology (EAU) guidelines recommend performing PLND for patients with ⩾2% and ⩾5%
risk of pathological node positive (pN+) disease, respectively, whereas the American
Urological Association (AUA) provides no
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specific recommendations and suggests, based on
expert opinion, that PLND be performed in
patients with unfavorable intermediate- or highrisk disease.5–7
Nevertheless, pre-RP nomograms have been
designed to predict risk of lymph node involvement (LNI), which in turn informs a surgeon’s
decision to perform PLND.8,9 These nomograms
were historically constructed to estimate LNI
based on systematic 12-core prostate biopsies
(PBx). With the introduction of multiparametric
magnetic resonance imaging (mpMRI), cognitive
or fusion targeted biopsies (TBx) have become
increasingly prevalent, sometimes in the absence
of traditional systematic biopsies (SBx). Current
nomograms may not be applicable to men presenting with TBx core data.10,11
Herein, we aimed to examine the practical application of mpMRI TBx data using established preRP nomograms and its potential implications on
RP perioperative decision-making. We hypothesize that current pre-RP nomograms may be suboptimal in estimating the risk of LNI for men
diagnosed with PCa via mpMRI TBx.
Furthermore, we developed a novel method to
‘augment’ mpMRI TBx cores to improve nomogram outcome predictions to better identify
appropriate candidates for PLND.
Methods
Following institutional review board approval
(ref. #18D.597), retrospective chart review of a
prospectively maintained RP database was conducted at Thomas Jefferson University (TJU) and
the University of Toronto (UT). All men with
positive mpMRI TBx with available biopsy
pathology from 2015 to 2018 were included.
Positive mpMRI was inclusive of any lesions with
a PI-RADS (Prostate Imaging–Reporting and
Data System) score of 3–5. Standard PLND was
completed in all men undergoing RP at TJU
while standard PLND was completed selectively
in men with ⩾2–5% risk of LNI at UT (surgeon
preference). PBx pathology reports were
abstracted for date of procedure, technique (targeted or both targeted and systematic), and
Gleason score (total and core level data). RP
pathology synoptic reports were abstracted for
date of procedure, completion of LND, T-stage,
N-stage, final Gleason score, surgical margin status, extracapsular extension (ECE), and seminal

2

vesicle invasion (SVI). Organ confined disease
(OCD) was defined as ⩽pT2N0 on RP pathology. Age, race, clinical stage, and preoperative
prostate-specific antigen (PSA) were also documented for all patients.
Two nomograms were utilized in this study: the
Kattan Memorial Sloan Kettering Cancer Center
(MSKCC) nomogram and the 2012 Briganti
nomogram.8,9 Each patient was individually
assessed with both nomograms using the following iterations: (1) ‘Targeted’ (T), utilizing TBx
core data only; (2) ‘Targeted and Systematic’
(TS), utilizing all available PBx core data; and (3)
‘Targeted Augmented’ (TA), utilizing TBx core
data alone while assuming negative remaining
PBx cores for a total of 12 cores (Figure 1).
Nomogram outputs were abstracted for each
patient: LNI (Briganti) and OCD, ECE, LNI,
SVI (MSKCC).
Mean ± standard deviation (SD) nomogram
outcomes were compared between the T and
TA iterations. Paired Student’s t test was utilized to calculate statistical differences between
the two iterations. All statistical tests were twotailed and a p value <0.05 was considered statistically significant. RP pathology was used to
validate nomogram outcomes. Clinically significant impact on management was defined as a
change in risk above or below 2% (Δ2) or 5%
(Δ5), based on current guidelines recommendations, that may impact decision to complete
PLND.5,6
Results
Patients demographics
A total of 217 men met inclusion criteria. Of the
159 men from UT, 90 (56.6%) underwent PLND,
while all 58 men from the TJU cohort underwent
standard PLND. Table 1 highlights key demographic data and preoperative parameters for the
entire cohort and individual institutions. Of the
190 patients who underwent both TBx and SBx,
16 patients (8.4%) had discordant pathology: all
16 demonstrated Gleason score upgrading on SBx
cores when compared with TBx.
Nomogram and RP outcomes
In Table 2, the MSKCC and Briganti nomogram risk outcomes were compared between the
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Figure 1. A sample patient who underwent MRI-US fusion targeted biopsy in addition to a 12-core systematic
biopsy (total 16 cores) is depicted on the left. He had 2/12 cores positive on systematic biopsy and 3/4 cores
positive on targeted biopsy. Biopsy core data was assessed according to the three iterations as depicted on
the right.

T and TA iterations. Comparison of nomogram
outcomes for individual cohorts are depicted in
Supplementary Table 1A and 1B. On average,
the TA iteration had more conservative
journals.sagepub.com/home/tau

nomogram predictions than the T iteration for
all outcomes. These differences were statistically significant at p < 0.001 in both nomograms at both institutions.
3
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Table 1. Patient demographics.
Entire cohort

TJU cohort

UT cohort

p value

Total number, n (%)

217 (100.0)

58 (26.7)

159 (73.3)

–

Age, years (mean ± SD)

62.4 ± 6.5

61.5 ± 6.1

62.7 ± 6.7

0.230

PSA, ng/ml (mean ± SD)

8.6 ± 7.7

10.9 ± 10.7

7.7 ± 6.1

0.007

Clinical T stage, n (%)

<0.001

cT1

138 (63.6)

50 (86.2)

88 (55.3)

cT2

77 (35.5)

7 (12.1)

70 (44.0)

cT3

2 (0.9)

1 (1.7)

1 (0.6)

Prostate biopsy technique, n (%)

0.572

Targeted only

27 (12.4)

6 (10.3)

21 (13.2)

Targeted and Systematic

190 (87.6)

52 (89.7)

138 (86.8)

Prostate biopsy grade group, n (%)

0.137

Grade group 1

50 (23.0)

8 (13.8)

42 (26.4)

Grade group 2

89 (41.0)

24 (41.4)

65 (40.9)

Grade group 3

45 (20.7)

13 (22.4)

32 (20.1)

Grade group 4

22 (10.1)

10 (17.2)

12 (7.5)

Grade group 5

11 (5.1)

3 (5.2)

8 (5.0)

PSA, prostate-specific antigen; TJU, Thomas Jefferson University; UT, University of Toronto.

In only 21 (9.7%) cases, the TA iteration had
worse LNI outcomes than the T iteration. Two of
these patients had a higher percentage of positive
cores on the TA iteration as they both had more
than 12 targeted cores sampled on the initial
biopsy. For the remaining 19 cases, we noted that
all patients had 100% positive core involvement
on their targeted cores alone, and only their
MSKCC nomogram outcomes were affected.
Table 2 also depicts the comparison of nomogram outcomes with final RP pathology. Risk of
LNI was calculated in all patients who underwent PLND while ECE, SVI, and OCD was calculated for all patients regardless of whether
PLND was performed. Comparison for nomogram and RP outcomes for individual institutions are depicted in Supplementary Table 1A
and 1B. When compared with RP pathology, the
TA iteration was a better approximation than
the T iteration for LNI, ECE, SVI, and OCD in
both nomograms.
4

Clinically significant impact on management
Table 3 represents patients whose risk of LNI
crossed the 2% (Δ2) or 5% (Δ5) threshold across
iterations. When comparing TA and T iterations,
16.6–25.8% met Δ2 criteria and 20.3–39.2% met
Δ5 criteria in the entire cohort. Of the 124 patients
that underwent either Δ2/5 with the Briganti
nomogram, 17 (13.7%) of them underwent both
Δ2 and Δ5: 6 (35.0%) from the TJU cohort and
11 (65.0%) from the UT cohort. No patients
underwent both Δ2 and Δ5 with the MSKCC
nomogram.
Utilizing the TS iteration as an internal
validation
Finally, as an internal validation, in a subset of
patients who underwent both SBx and TBx
(n = 190), we compared their TA and T outcomes to their TS outcomes for LNI risk. This
data is depicted in Table 4. In both nomograms,
the TA iteration was a better approximation to
journals.sagepub.com/home/tau
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Table 2. Comparison of nomogram outcomes between T and TA iterations and with pathology outcomes.
Pre-RP nomogram
outcomes, mean
(SD)

MSKCC (T)

MSKCC (TA)

Mean
difference
(SEL-ORIG)

Briganti (T)

Briganti
(TA)

Mean
difference
(SEL-ORIG)

RP
pathology
outcomes

LNI*

11.40 (10.62)

8.00 (8.61)

–3.40

18.18 (17.29)

6.38 (9.83)

–11.80

6.04†

ECE

59.61 (11.85)

53.10 (13.75)

–6.52

–

–

–

42.40†

SVI

9.73 (9.28)

5.67 (7.04)

–4.06

–

–

–

7.37†

OCD

38.64 (12.51)

45.38 (14.62)

6.75

–

–

–

54.84†

*Risk of LNI only includes patients who underwent PLND during RP (n = 148).
†TA is better than T in predicting RP pathology.
ECE, extracapsular extension; LNI, lymph node involvement; OCD, organ-confined disease; RP, radical prostatectomy; SD, standard deviation;
SVI, seminal vesicle invasion; T, Targeted; TA, Targeted Augmented.

Table 3. Clinically significant impact on management between T and TA iteration.
MSKCC, n (%)
Entire cohort

Briganti, n (%)

T Bx only (n = 27)

MSKCC, n (%)

Briganti, n (%)

T+S Bx (n = 190)

MSKCC, n (%)

Briganti, n (%)

All Bx (n = 217)

Δ2

3 (11.11)

3 (11.11)

33 (17.37)

53 (27.89)

36 (16.59)

56 (25.81)

Δ5

4 (14.81)

9 (33.33)

40 (21.05)

76 (40.00)

44 (20.28)

85 (39.17)

TJU cohort

T Bx only (n = 6)

T+S Bx (n = 52)

All Bx (n = 58)

Δ2

1 (16.67)

1 (16.67)

4 (7.69)

18 (34.62)

5 (8.62)

19 (32.76)

Δ5

1 (16.67)

2 (33.33)

14 (26.92)

20 (38.46)

15 (25.86)

22 (37.93)

UT cohort

T Bx only (n = 21)

T+S Bx (n = 138)

All Bx (n = 159)

Δ2

2 (9.52)

2 (9.52)

29 (21,01)

35 (25.36)

31 (19.50)

37 (23.27)

Δ5

3 (14.29)

7 (33.33)

26 (18.84)

56 (40.58)

29 (18.24)

63 (39.62)

Bx, biopsy; T, Targeted; TJU, Thomas Jefferson University; T+S, Targeted and Systematic; UT, University of Toronto.

the patient’s TS outcomes than the T iteration in
71–82% of cases.
Discussion
The addition of mpMRI as a diagnostic tool has
allowed for better sampling and detection of clinically significant PCa. mpMRI fusion TBx have
become increasingly utilized in the diagnosis and
surveillance of PCa. With multiple prospective
studies now demonstrating its ability to better
identify clinically significant PCa and limit identification of low-risk PCa,12–14 mpMRI fusion biopsies are now recommended by international

journals.sagepub.com/home/tau

guidelines in the setting of repeat biopsies and
active surveillance.5,6,15,16 Indeed, the recent multicenter randomized controlled PRECISION trial
demonstrated the superiority of mpMRI TBx over
TRUS SBx in detecting PCa in biopsy-naïve
men.13 Systematic reviews by Wu and Valerio also
report the efficacy of mpMRI TBx over SBx.17,18
However, while the optimism for TBx is high, it
should be noted that SBx still identifies clinically
significant PCa missed by TBx and mpMRI fusion
biopsy outcomes are highly variable based on
institution.12,19 As such, at this time, the general
consensus is that TBx should be done in conjunction with SBx to maximize diagnostic yield.20

5

Therapeutic Advances in Urology 11
Table 4. Approximation of TA and T iteration to the TS.

Entire cohort (n = 190)

TJU cohort (n = 52)

UT cohort (n = 138)

MSKCC, n (%)

Briganti, n (%)

TA closer to TS

135 (71.1)

156 (82.1)

T closer to TS

34 (17.9)

18 (9.5)

No difference

21 (11.1)

16 (8.4)

TA closer to TS

25 (48.1)

35 (67.3)

T closer to TS

21 (40.4)

16 (30.8)

No difference

6 (11.5)

1 (1.9)

TA closer to TS

110 (79.7)

121 (87.7)

T closer to TS

13 (9.4)

2 (1.5)

No difference

15 (10.9)

15 (10.9)

T, Targeted; TA, Targeted Augmented; TJU, Thomas Jefferson University; T+S, Targeted and Systematic; UT, University of
Toronto.

With mpMRI serving as such an important biomarker for clinically significant PCa, there exists
an urgent need to integrate mpMRI data into preRP risk tools to improve patient stratification during initial risk assessment.21,22 A recent study by
Briganti and colleagues aimed to address this
need by developing a novel nomogram that considers relevant mpMRI data and clinical parameters.23 These additional variables include clinical
staging (OCD, ECE, SVI) on mpMRI, maximum
lesion diameter and Gleason Grade Group on
TBx. With an area under the receiver operating
characteristic curve (AUC) of 0.84, their nomogram demonstrated a higher net benefit compared with the 2012 Briganti, 2017 Briganti, and
MSKCC models, which are currently available
models developed using standard biopsies
alone.8,9,24 However, these results have yet to be
validated.
As clinicians often use preoperative nomograms
to complement their decision making to perform
PLND during RP, practical utilization of these
established pre-RP nomograms may be problematic, especially in men presenting with only TBx
cores. Therefore, we sought an intuitive way to
incorporate targeted cores into current pre-RP
nomograms when systematic cores are absent. As
the number of TBx to a single region of interest
ranges between 2 and 4,16,25 we developed a
model to augment TBx core data to facilitate use
of established pre-RP nomograms. This augmentation is done by utilizing only the available
6

targeted core data while assuming negative
remaining biopsy cores for a total of 12 cores
(Figure 1).
In our study, the predicted risk of LNI for TBx
data after augmentation for the entire cohort
(regardless of PLND) decreased by 2.85% and
10.44% using the MSKCC and Briganti nomograms, respectively (data not shown). More
importantly, nomogram predictions after augmentation of TBx data appears to be a closer
approximation of the actual risk of LNI based on
patients’ RP pathology (Table 2). Furthermore,
with the MSKCC nomogram, utility of the TA
iteration also better predicts ECE, OCD, and
SVI.
Unlike the Briganti nomogram, biopsy core data
is not required when estimating RP outcomes
using the MSKCC nomogram.8,9 In cases where
PBx data is absent, nomogram outcomes, after
utilizing remaining preoperative parameters, are
predicted based on the average value of the represented cohort within the database. As such, this
may account for the reason why 19 patients had
worse LNI outcomes predicted by the TA iteration than the T iteration. Indeed, these actually
reflect a systematic error in the MSKCC nomogram, as patients with 100% positive core involvement revert to nomogram outcomes that ignore
core involvement altogether. Therefore, in these
patients, these nomogram outcomes could not be
interpreted accurately as the assumptions made
journals.sagepub.com/home/tau
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by the nomogram may not necessarily reflect the
patient’s true outcome.
The consistent differences in nomogram outcomes between the T and TA iterations question
the application of pre-RP nomograms in patients
who only undergo TBx. It also brings to the forefront whether PLND performed on these patients
are justified. Aside from incurring higher costs
and increased operative time, PLND completion
may also increase complication risks. PLND at
the time of RP is associated with pelvic lymphocele formation in 2–9% of patients.26 Other
potential complications include lymphedema,
venous thromboembolism, and injury to the ureter or surrounding neurovasculature.27 From our
results, 17–39% of patients who underwent
PLND at the time of RP did not actually meet
criteria for PLND based on current guideline recommendations after utility of the TA iteration.5,6
Despite the increased diagnostic yield of mpMRI
fusion TBx, most patients still undergo SBx in
addition to TBx. In our study, the TS iteration,
which incorporates all available core data, most
accurately reflects the true LNI risk in this patient
population. When comparing TA or T with TS,
we found that consideration of targeted cores
only revealed suboptimal risk predictions, further
justifying the need to consider systematic or augmented cores in preoperative risk nomograms.
Although the PROMIS trial reported mpMRI
TBx having a higher sensitivity and negative predictive value than standard TRUS biopsies for
detecting clinically significant PCa, its low specificity (41%) indicates that mpMRI is not a perfect
discriminatory test.12 Moreover, results from the
recently published ASIST trial demonstrated that
mpMRI fusion TBx did not increase upgrading
rates when compared with SBx alone, that both
SBx and TBx missed significant cancer at almost
equal rates, and that there are significant differences in TBx outcomes based on institution and
level of expertise. The authors also suggested that
patients with higher risk of disease should undergo
SBx regardless of mpMRI findings.19 These studies further support the increasing evidence that
SBx should be continued in addition to TBx.
We acknowledge that the study is not without its
limitations. First, our study design was retrospective in nature with its inherent limitations. No
central pathology review of PBx or RP pathology
was utilized, though all were read and interpreted

journals.sagepub.com/home/tau

by experienced genitourinary pathologists. We
also acknowledge that our concept of augmenting
TBx data with negative systematic cores for a total
of 12 cores may be flawed. First, the number of
targeted cores obtained from each region of interest may vary, thereby affecting the percentage of
12 cores attributed to TBx and SBx. In addition,
as PCa is known to be a multifocal disease, presuming negative cores in the remainder of the
prostate may artificially improve a patient’s risk
profile; yet, patients only receiving TBx inherently
have the risk of missed clinically significant PCa
anyway. Finally, both nomograms utilized in our
study were developed using distinctly different
patient cohorts (different era of treatment, variable surgeon preferences, and techniques with
regards to degree of lymph node dissection, etc.),
which may impact nomogram accuracy.
Ultimately, however, the goal of this study was to
highlight the drastic misrepresentation of disease
burden in men who undergo TBx alone and the
need for new nomograms that account for
mpMRI TBx. In the interim, utilization of an
augmented nomogram may help provide guidance for surgical planning.
Conclusion
As mpMRI fusion biopsies become more commonplace in the diagnosis and management of
PCa, there must be better incorporation of fusion
biopsy data into future nomograms. TBx data,
used in isolation in current nomograms, significantly overestimate final pathology outcomes and
cannot be used reliably. Augmentation with negative systematic cores may serve as a bridge in the
interim to help guide surgical planning.
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